Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4436 - Biomarker-Guided Enrichment of the Antitumor Activity of Margetuximab (M) plus Pembrolizumab (P) in Patients with Advanced HER2+ Gastric Adenocarcinoma (GEA)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Clinical Research;  Translational Research

Tumour Site

Gastric Cancer

Presenters

Daniel Catenacci

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

D.V.T. Catenacci1, H. Park2, H.E. Uronis3, Y. Kang4, M. Ng5, P. Gold6, J. Lacy7, P.C. Enzinger8, S. Park9, K. Lee10, J. Yen11, J. Odegaard12, A. Franovic13, J. Baughman14, J. Muth15, A. Wynter-Horton16, T. Wu17, J. Wigginton18, J.K. Davidson-Moncada19, Y. Bang20

Author affiliations

  • 1 Medicine, The University of Chicago Medical Centre, 60653 - Chicago/US
  • 2 Oncology, Washington University, 63110 - St. Louis/US
  • 3 Department Of Medicine, Duke University Medical Center, Durham/US
  • 4 Division Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 5 Division Of Medical Oncology, National Cancer Centre (NCC), Singapore, 169610 - Singapore/SG
  • 6 Gi Oncology, Swedish Medical Center, Seattle/US
  • 7 Medical Oncology, Yale School of Medicine, New Haven/US
  • 8 Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, 2215 - Boston/US
  • 9 Hematology-oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, 06351 - Seoul/KR
  • 10 Department Of Internal Medicine, Seoul National University Bundang Hospital, Seoul/KR
  • 11 Bioinformatics, Guardant Health, Redwood City/US
  • 12 Guardant Health, Redwood City/US
  • 13 Medical Oncology, Guardant Health, 94063 - Redwood City/US
  • 14 Clinical Development, MacroGenics, Inc., Brisbane/US
  • 15 Research, MacroGenics, Inc., Rockville/US
  • 16 Clinical Operations, MacroGenics, Inc., Rockville/US
  • 17 Biostatistics, MacroGenics, Inc., Rockville/US
  • 18 Clinical, MacroGenics, Inc., 20850 - Rockville/US
  • 19 Clinical Development, MacroGenics, Inc., 20850 - Rockville/US
  • 20 Internal Medicine (medical Oncology), Seoul National University Hospital, 110-744 - Seoul/KR
More

Resources

Abstract 4436

Background

Trastuzumab (T) + chemo is standard 1st line therapy (tx) for HER2+ GEA patients (pts). Pts typically progress in 6-8 months, with loss of HER2 positivity in 40% of treated pts. No anti-HER2 agents are approved in the post-T setting. We report the results of M, an anti-HER2 monoclonal antibody Fc-optimized for antibody-dependent cellular cytotoxicity, + P in HER2+ GEA pts and describe potential strategies for biomarker-guided response enrichment based on ERBB2 amplification and/or PD-L1 expression.

Methods

HER2+, PD-L1-unselected, 2nd line GEA pts post T progression received M (15 mg/kg Q3) + P (200 mg Q3). Safety, objective response rate (ORR), median overall and progression-free survival (mOS, mPFS), disease control rate (DCR), circulating-tumor DNA (ctDNA), and tumor PD-L1 expression were assessed.

Results

At data cutoff, 60 GEA pts were dosed in cohort expansion; 16.7% had treatment-related adverse events ≥ Grade 3. Overall, 21.6% had objective response (OR), 10 confirmed and 3 unconfirmed. DCR was 55% and mOS was 15.6 mos (95% CI: 7.26, NR). In GC pts, OR occurred in 10 of 34 (29.4%), mPFS was 4.24 mos (95% CI: 1.68, 5.62), and mOS not reached. Notably, only 31 of 51 (61%) of pts with baseline ctDNA testing showed ERBB2-amplification; 21 of 30 (70%) of pts with fresh tumor biopsy were HER2 3+ by IHC (80% concordance). Tumors were PD-L1+ positive in 13 of 28 (46%) pts tested, with higher rates in pts with GC. The presence of ERBB2 amplification by ctDNA and tumor PD-L1 expression by IHC were both associated with increased probability of OR: 33.3% v. 10.5% (p = 0.0948) and 43.8% v. 16.7% (p = 0.0769), respectively. ORR was 5 of 8 (62.5%) in ERBB2 amplified/PD-L1+ pts. In pts with activating HER2 mutations DCR was 11/15 (73%), indicating ADCC.

Conclusions

Consistent with prior tissue-based reports, many GEA pts progressing on T have lost ERBB2 amp. ERBB2 status by ctDNA NGS post-T could help identify patients more likely to respond to M+P, particularly in PD-L1+ pts. Our results suggest that M+P is well tolerated and has encouraging preliminary activity in 2nd line HER2+ GEA. Biomarker selection may further enrich for responding pts, advancing a potential chemo-free regimen in this population.

Clinical trial identification

NCT02689284.

Legal entity responsible for the study

MacroGenics, Inc.

Funding

MacroGenics, Inc.

Editorial Acknowledgement

Not Applicable

Disclosure

D.V.T. Catenacci: Honoraria: Merck, BMS, Lilly, Genentech/Roche, Amgen, Taiho, Guardant Health, Foundation Medicine; Research funding: Genentech/Roche. H.E. Uronis: Consulting, Advisory role: Bristol-Myers Squibb; Research funding: Genentech/Roche, Bristol-Myers Squibb, Advaxis, MacroGenics, Merck. Y-K. Kang: Consulting, Advisory role: Lily/ImClone, Taiho Pharmaceutical, Ono Pharmaceutical, Roche/Genentech, Novartis; Research funding: LSK Biopharma. M. Ng: Consulting, Advisory role: MSD Oncology, Bristol-Myers Squibb; Honoraria: Taiho Pharmaceutical; Research funding: ASLAN Pharmaceuticals. J. Lacy: Advisory board: Celgene. P.C. Enzinger: Consultant: Astellis, Celgene, FivePrime, Lilly, Loxo, Merck, Taiho. K-W. Lee: Research funding: AstraZeneca/Medimmune, Green Cross Corp, MSD, Ono Pharmaceutical, Merck KGaA, Five Prime Therapeutics, MacroGenics, ASLAN Pharmaceuticals, LSK BioPharma, Array BioPharma, Pharmacyclics, Pfizer. J. Yen, A. Franovic: Employee: Guardant Health. J. Odegaard: Employee, Stock holder: Guardant Health. J. Baughman: Employee: MacroGenics, Inc. J. Muth, T. Wu, A. Wynter-Horton: Employee, Stock ownership: MacroGenics, Inc. J. Wigginton, J.K. Davidson-Moncada: Employee, Leadership, Stock and other ownership interests: MacroGenics. Y-J. Bang: Consulting, Advisory role: Samyang; Research funding: AstraZeneca/Medimmune, Novartis, Genentech/Roche, MSD, Merck/Serano, Bayer, GlaxoxSmithKline, Bristol-Myers Squibb, Pfizer, Lilly, Boehringer Ingelheim, MacroGenics, Boston Miomedical, kFive Prime Therapeutics, Chong Kun Dang Pharmaceutical, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda, BeiGene, Curis, Green Cross Corp. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.